Diabetes
Conditions
Interventions
In-hospital asymptomatic malignant tumour case group:None
Group of hospitalised patients with diabetes during their first admission and without malignant tumours:None
Sponsors
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Case Group (Diabetes with Asymptomatic Malignant Tumour Detected During Hospitalisation) Inclusion Criteria: 1. Patients diagnosed with diabetes meeting the criteria of the Chinese Diabetes Prevention and Treatment Guidelines (2024 Edition); 2. Malignant tumours newly identified during current hospitalisation: primarily confirmed by pathology; where pathology is not performed due to objective constraints, diagnosis must be strongly suggested by imaging and confirmed through specialist consultation or multidisciplinary team (MDT) discussion records; 3. Meets "asymptomatic screening" criteria: admission unrelated to tumour-associated symptoms, no definite organ system symptoms at diagnosis; incidentally detected during routine or systematic screening during current hospitalisation; 4. Complete key metabolic and relevant laboratory parameters; Control group (diabetes without in-hospital detection of malignancy) Inclusion criteria: 1. Patients diagnosed with diabetes meeting the diagnostic criteria of the Chinese Diabetes Prevention and Treatment Guidelines (2024 Edition); 2. Frequency-matched with the case group by age and diabetes duration (ratio approximately 1:1), with gender composition difference <=5 percentage points; 3. No evidence of malignancy in clinical or examination data during current hospitalisation (including imaging studies showing no suspicious malignant lesions); 4. Complete key metabolic and relevant laboratory parameters.
Exclusion criteria
Exclusion criteria: Case group (diabetes with asymptomatic detection of malignancy during hospitalisation) exclusion criteria: 1. History of malignancy or hereditary tumour syndromes; 2. Concurrent severe organ dysfunction (e.g., decompensated cardiac/hepatic/renal failure); 3. Systemic hormonal or immunosuppressive therapy lasting >=3 months within the past 5 years, or immunosuppressed status (solid organ transplant recipients, HIV infection, etc.); 4. Concurrent acute metabolic disorder (DKA, HHS) or acute infection during current hospitalisation; Control group (diabetes without in-hospital detection of malignancy) exclusion criteria: 1. Any history of malignancy; 2. Imaging evidence of uncharacterised or suspicious malignant lesions (e.g., TI-RADS >=4 or BI-RADS >=4); 3. Concurrent acute metabolic disorder (DKA, HHS) or acute infection during current hospitalisation; 4. Continuous systemic hormone or immunosuppressive therapy for >=3 months within the past 5 years, or immunosuppressed status (solid organ transplant recipients, HIV infection, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incident detection of asymptomatic malignancy during the index hospitalization.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Early in-hospital glycaemic control and glycaemic variability indices;Beta-cell function: two-hour post-load C-peptide;Lipid and nutritional markers: apolipoprotein A-I and serum albumin;Serum tumor marker panel; | — |
Countries
China
Contacts
Public ContactShichun Du
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Outcome results
None listed